Crossmark

Pharmacokinetic and pharmacodynamic characterization of remimazolam in older Japanese adults who underwent general anesthesia at early stage of infusion

Crossref DOI link: https://doi.org/10.1038/s41598-025-10015-z

Published Online: 2025-07-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ueshima, Satoshi https://orcid.org/0000-0002-8828-1083
Nagahara, Serina

Nakaya, Kenta

Kawamura, Mayu

Hira, Daiki

Matsuura, Yu

Toyama, Hiroaki

Kawamae, Kaneyuki

Kakumoto, Mikio
License Information

Text and Data Mining valid from 2025-07-10

Version of Record valid from 2025-07-10
More Information

Article History

Received: 15 April 2025

Accepted: 1 July 2025

First Online: 10 July 2025

Declarations

:

: The Authors K. K. and M. K. were kindly gifted remimazolam, CNS-7054, and their internal standards from Paion UK Ltd. (Richmond, United Kingdom). Other authors have no competing interest.

: This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Review Board of Ritsumeikan University Biwako-Kusatsu Campus (approval number BKC-IRB-2020-084) and the Ethical Review Committee of Yamagata University Faculty of Medicine (Approval number 2020–284).

: All participants provided written informed consent.

Document is current

Any future updates will be listed below